In addition to supportive transfusions, do you consider other interventions for symptomatic anemia and thrombocytopenia associated with chronic neutrophilic leukemia?
The patient is 94 years old and not a candidate for intensive chemotherapy. Neutrophilia is controlled with low-dose hydroxyurea. She harbors a CSF3R mutation and is without significant splenomegaly. Is there any role for ESAs or TPO agonists in this setting?
1 Answer
Mednet MemberInvited Expert
Hematology · University of Chicago
Answered on
Assuming the CSF3R mutation that is seen is the T618I mutation, you can consider ruxolitinib. Dao et al., PMID 31880950, reported on a prospective trial of ruxolitinib in 44 patients with CNL or atypical CML. The overall response rate was 35%. However, responses were enriched in patients with CSF3R-...
Join for free or sign in to see the full answer